anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods for filling packagings with at least one medication include producing filling instructions, operating a packaging station to fill packagings, and verifying that each of the packagings is filled correctly. The production of filling instructions includes an allocation of medications to separated compartments in the packagings. Each packaging receives a single medication pass for a specified time on a specified day, or a medicine pass for administration on an as needed basis. The packaging station may include a manual packaging station at which an operator follows prompts to move canisters of medications, pills from the canisters, and trays of packagings to fill the packagings. The manual packaging station includes a shutter assembly with shutters configured to selectively provide access to only one compartment in each packaging at a time, thereby reducing the likelihood of filling errors. Apparatus for filling packagings may include the same manual packaging station.
PROBLEM TO BE SOLVED: To produce a ceramide synthesis accelerator expected to improve rough skin and display treatment and improvement effects on various skin troubles and provided with excellent stability in the lapse of time by including a fungous culture having a ceramide synthesis accelerating function and butylene glycol. SOLUTION: This accelerator is obtained by including a fungous culture having a ceramide synthesis accelerating function [lactic acid bacteria culture (e.g. Streptococcus thermophilus or Lactobacillus bulgaricus), Bifidus bacterium culture [e.g. Bifidobacterium bifidum], mushroom cell body (e.g. Lentinus edodes or Celtis sinensis) and yeast plant (e.g. Saccharomyces cerevisiae or Endomyces magnusii) and (B) 1,3-butylene glycol. In the accelerator, the weight of the component A is 3 to 6 times that of the component B. The amount of addition is pref. 0.001 to 10 wt.% when the accelerator is added to a cultured epidermal cell system so as to accelerate a ceramide synthesis, and it is pref. 0.01 to 20 wt.% when added to agent for external use for skin.
BACKGROUND: The surplus cytokines remaining after use in the early stages of the inflammatory response stimulate immune cells even after the response is over, causing a secondary inflammatory response and ultimately damaging the host, which is called a cytokine storm. Inhibiting heat shock protein 90 (Hsp90), which has recently been shown to play an important role in regulating inflammation in various cell types, may help control excessive inflammatory responses and cytokine storms.
METHODS: We discovered an anti-inflammatory compound by measuring the inhibitory effect of CD86 expression on spleen DCs (sDCs) using the chemical compounds library of Hsp90 inhibitors. Subsequently, to select the hit compound, the production of cytokines and expression of surface molecules were measured on the bone marrow-derived DCs (BMDCs) and peritoneal macrophages. Then, we analyzed the response of antigen-specific Th1 cells. Finally, we confirmed the effect of the compound using acute lung injury (ALI) and delayed-type hypersensitivity (DTH) models.
RESULTS: We identified Be01 as the hit compound, which reduced CD86 expression the most in sDCs. Treatment with Be01 decreased the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS. Under the DTH model, Be01 treatment reduced ear swelling and pro-inflammatory cytokines in the spleen. Similarly, Be01 treatment in the ALI model decreased neutrophil infiltration and lower levels of secreted cytokines (IL-6, TNF-α).
CONCLUSIONS: Reduction of CD80 and CD86 expression on DCs by Be01 indicates reduced secondary inflammatory response by Th1 cells, and reduced release of pro-inflammatory cytokines by peritoneal macrophages may initially control the cytokine storm.
BACKGROUND: Chronic pain is acomplexhealth issue. Compared to acute pain, which has a protective value, chronic pain is defined as persistent pain after tissue injury. Few clinical advances have been made to prevent the transition from acute to chronic pain. Electroacupuncture (EA), the most common form of acupuncture, is widely used in clinical practice to relieve pain.
METHODS: The hyperalgesic priming model, established via a carrageenan injection followed by a prostaglandin E2 injection, was used to investigate the development or establishment of chronic pain. We observed the hyperalgesic effect of EA on rats and investigated the expression p38 mitogen-activated protein kinase, interleukin-33 (IL-33), and its receptor ST2 in astrocytes in the L4-L6 spinal cord dorsal horns (SDHs) after EA. The IL-33/ST2 signaling pathway in SDH is associated with the development of chronic pain.
RESULTS: EA can reverse the pain threshold in hyperalgesic priming model rats and regulates the expression of phosphorylated p38, IL-33, and ST2 in astrocytes in the L4-L6 SDHs. We discovered that EA raises the pain threshold. This suggests that EA can prevent the development or establishment of chronic pain by inhibiting IL-33/ST2 signaling in the lower central nervous system.
CONCLUSIONS: EA can alleviate the development or establishment of chronic pain by modulating IL-33/ST2 signaling in SDHs. Our findings will help clinicians understand the mechanisms of EA analgesia.
Currently, there is no cure for Parkinson's disease (PD) and although medication offers symptom reduction, there are many negative side effects associated with medication use. Thus, there has been an increased emphasis on exercise interventions for symptom reduction. Recent research has shown that both sensory attention focused exercise (SAFEx) and strength training interventions improved disease severity more so than other exercise interventions (such as aerobic, aquatic and no exercise). Upon closer examination, SAFEx showed further symptom improvements than the strength training program. Thus exists the need to further examine SAFEx using a standardized protocol - a single-blind randomized double-crossover trial - that has been used sparingly in exercise interventions. In addition, the 30-second chair stand has been implemented into the testing protocol, as it has been shown to be a reliable measurement of functional strength for older adults. This test was implemented in order to identify the functional strength gains, if any, that are associated with SAFEx. It is hypothesized that the SAFEx intervention will improve disease symptoms in PD, and that the results will not be due to strength gains.
A composition is provided that includes a fish spawn protein isolate having an anti-inflammatory effect on mammalian skin. A natural product extract is also present that includes unsaturated fatty acids and sterols. The natural product extract has anti-oxidant activity and collagenase inhibition activity. An emulsifier is provided to form a mixture of the isolate and the extract. A kit is provided inclusive of the composition and instructions for the application the composition to user skin. A process of improving skin appearance is provided that includes the application of the composition to the skin of a mammal at a level of from 1 x 10 -6  to 0.1 mg of the isolate and 2 x 10 -7  to 0.02 mg of the unsaturated fatty acids per square cm of skin at least three times per week to achieve the improvement of the skin appearance.
Sulphation of carbohydrate gums (poly-saccharides) without significantly modifying the basic carbohydrate structure is carried out in a solvent contng., as sulphating agent, the reaction product of SO3 and a Lewis base. The carbohydrate is made ready for this process by the following treatment: Water-swollen gum particles are suspended in a water-miscible substitute liquid. This liquid does not exhibit an irreversible reaction with the sulphating agent. Its vapour pressure is below that of water and it is miscible with the solvent for the sulphating agent or is the same as this solvent. When the substitute liquid is removed, water-free particles which are suitably activated for the above sulphation process are obtained. Claimed uses include application as suspension agent in a beverage comprising cocoa particles, milk and sweetener, and as binding agent in toothpaste. Mol. structure of the starting carbohydrates is largely preserved. Characteristics are improved, including suspension props in water.
Non-activated tissue-regeneration polypeptides (TRPs) and the preparation methods thereof are disclosed. The TRPs contain: a protein transduction domain (PTD) making the polypeptides to permeate a cell membrane without cell membrane receptors; a furin activation domain (FAD) which has at least one proprotein convertase cleavage site and which can be cleaved by the proprotein convertase and activate a tissue regeneration domain (TRD) in cells; and a tissue regeneration domain (TRD) which can be activated by the proprotein convertase cleavage of the FAD to stimulate the growth or formation of tissues or to induce the regeneration of tissues. The TRPs can be practically mass-produced by the culture of bacteria, such as recombinant  E. coli , and are in a non-activated state before in vivo administration. Thus, their production cost is only a few tenths of the prior active proteins having uses similar thereto, and processes for their separation, purification, handling, storage and administration are significantly simple and convenient. The in vivo administration of the TRPs can stimulate the formation or regeneration of tissues, such as bones or cartilages, or improve the fibrosis and cirrhosis of organs, such as kidneys, liver, lungs and heart by pharmacological mechanisims completely different from those of prior rhBMPs or TGF-β proteins. Accordingly, the TRPs will be useful as drugs having new mechanisms.
Individuals between the ages of 18-65 who were diagnosed with CTS in the dominant hand and who volunteered to participate in the study were included. SF-36, Quick Disabilities of the Arm, Shoulder, and Hand (Q-DASH), Michigan Hand Outcomes Questionnaire and Boston Carpal Tunnel Questionnaire - Functional Status Scale will be used to assess activity and participation. The questionnaires will be filled out via Google Forms. Shapiro-Wilk test will be performed to determine the distribution of the data. Whether the dependent variables differ between groups will be analysed by One-way ANOVA (continuous). For significant F-test, an additional investigation of differences between groups will be performed with Gabriel's post hoc procedure.
Standard 4 x 4 min HIT at treadmill. First 7 min warm-up, then 4 sessions with 4 min walking/running at 80-95% of maximal heart rate, with 3 min of active rest in between. Ending with 5 min of cooling down. Two sessions per week for 26 weeks.
AIM: Endometrial changes in Japanese transgender men (TGM) on testosterone use remain elucidated. This study aims to present TGM with endometrial cancer and insights from a literature review of similar cases. Furthermore, we investigated the correlation between endometrial cancer and severe obesity in TGM who underwent gender-affirming surgery.
METHODS: Between July 2020 and April 2023, two groups were assessed: 2 TGM with endometrial cancer and 43 TGM without cancer who underwent gender-affirming surgery. A literature review for TGM with endometrial cancer was conducted. Clinical data were retrospectively collected, and histopathological evaluation of female genital organs was performed.
RESULTS: Two TGM with endometrial cancer and an additional four similar cases were identified through a literature search. These TGM had severe obesity (body mass index [BMI] ≥30 kg/m2) and long-term testosterone use, indicating a possible link between endometrial cancer and these factors. Subsequently, we investigated the 43 TGM without cancer. We revealed 30% with obesity (BMI ≥25), only three cases of severe obesity (BMI ≥30), and a significant correlation between testosterone use duration and BMI in TGM without cancer. Histological examination revealed focal proliferative endometrium in 51% of cases and polycystic ovarian changes in 77%.
CONCLUSIONS: Our observations suggest a potential link between severe obesity, prolonged testosterone use, and endometrial cancer in transgender men. Histological changes in the female genital tract highlighted frequent focal proliferative endometrium, even under testosterone therapy. Further research should focus on larger, multi-institutional studies to confirm these findings and establish endometrial cancer screening for Japanese TGM.
Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 42 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study. Clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire.
Cytotoxic chemotherapy is relatively ineffective for a large proportion of common cancers. Combining redox active molecules with certain chemotherapy regimens could increase their anti-cancer activity or protect host tissues from toxicity with no loss of anti-cancer activity. Research in this area has been advocated by cancer organizations, but previous clinical trials of combination chemotherapy and antioxidant therapy been small, poorly designed, and unsystematic. Appropriate study of this treatment concept requires a systematic, meticulous empirical approach similar to the one used in conventional cytotoxic drug discovery. This is a Phase I-II study designed to identify promising chemotherapy-antioxidant protocols and determine their acceptability and limiting toxicity in patients with relentlessly progressive cancers for which conventional chemotherapy is clinically indicated but is known to be minimally or marginally effective.

The tolerable dose of intravenous ascorbic acid (IVAA) for cancer patients with normal renal function not receiving chemotherapy is 1.5 g/kg per 90 to 120 minute infusion (Hoffer et al, Ann Oncol 2008;19:1969-1974). Side effects are minimal to non-existent. In this dose-escalating study the IVAA will be 0.9 g/kg per infusion for the first chemotherapy cycle, increasing to 1.5 g/kg per infusion in subsequent cycles, for the first 3 participants. If well tolerated as expected, the initial dose will be 1.5 g/kg per infusion for subsequent participants. Infusions will take place 2 or 3 times per week, bracketing the days of chemotherapy. Standard tolerance and adverse effect criteria will be used. Therapy will continue for a minimum of 2 months, and continue further in the event of disease stabilization or response, as determined from CT scan and biomarkers, with evaluations continuing every 2 months.
A multimodal human-robot interaction system for compensation movement of a hemiplegic upper limb includes a compensation monitoring module, a compensation evaluation module and a compensation reducing module. The compensation reducing module includes a robot and a virtual reality system. The robot assists the hemiplegic upper limb in performing rehabilitation training, and adjusts a training action according to a compensation monitoring result and evaluation of compensation to realize passive reducing of compensation movement of the hemiplegic upper limb. The compensation monitoring module acquires data during a rehabilitation therapy. The compensation evaluation module processes and analyzes comprehensive data of the hemiplegic upper limb to obtain the evaluation of compensation. The virtual reality system displays a rehabilitation training scene, a real-time movement posture of the hemiplegic upper limb and the evaluation of compensation and instructs a patient to reduce the compensation movement using visual display and voice feedback.
PROBLEM TO BE SOLVED: To obtain a composition for oral cavity containing ascorbic acids and a fatty acid and useful for preventing and treating periodontal diseases without causing coloring in the composition. SOLUTION: This composition is obtained by combinedly using 0.001-5wt.% ascorbic acid or its derivative with 0.001-10wt.% fatty acid or its salt (e.g. lauric acid) and further blending 0.01-5wt.% anionic or nonionic surfactant (e.g. alkylsulfuric acid salt) therewith. The composition can enhance preventing and treating effect on periodontal diseases. The composition is used by preparing the composition into a dentifrice, a mouth cleaning agent, a gingiva massage cream, a local coating agent, a troche, a chewing gum, etc.
The ability to fight or flee from a threat relies on an acute adrenergic surge that augments cardiac output, which is dependent on increased cardiac contractility and heart rate. This cardiac response depends on β-adrenergic-initiated reversal of the small RGK G protein Rad-mediated inhibition of voltage-gated calcium channels (CaV) acting through the Cavβ subunit. Here, we investigate how Rad couples phosphorylation to augmented Ca2+ influx and increased cardiac contraction. We show that reversal required phosphorylation of Ser272 and Ser300 within Rad's polybasic, hydrophobic C-terminal domain (CTD). Phosphorylation of Ser25 and Ser38 in Rad's N-terminal domain (NTD) alone was ineffective. Phosphorylation of Ser272 and Ser300 or the addition of 4 Asp residues to the CTD reduced Rad's association with the negatively charged, cytoplasmic plasmalemmal surface and with CaVβ, even in the absence of CaVα, measured here by FRET. Addition of a posttranslationally prenylated CAAX motif to Rad's C-terminus, which constitutively tethers Rad to the membrane, prevented the physiological and biochemical effects of both phosphorylation and Asp substitution. Thus, dissociation of Rad from the sarcolemma, and consequently from CaVβ, is sufficient for sympathetic upregulation of Ca2+ currents.
In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of participants will be recorded on diary cards.
INTRODUCTION: Chronic postsurgical neuropathic pain (CPSNP) and related static mechanical allodynia (SMA) is recognised as a significant long-term complication after breast cancer surgery (BCS). This study investigates the effectiveness of a novel laser acupuncture technique in treating CPSNP and SMA post-BCS whilst patients underwent standard cancer treatments.
METHODS: Thirty patients with significant breast area CPSNP and SMA (DN4 ≥ 4) were treated with 60Milliwatt, 658nm laser acupuncture at Austin Hospital between January 2021 and 2024. Patient data was analysed retrospectively: 29 with CPSNP, 22 with SMA. The cohort had exposures to pain aggravating cancer therapies (e.g. chemotherapy, radiotherapy and antihormonal medications). An online patient questionnaire assessed treatment outcomes qualitatively.
RESULTS: Patients received an average of 6·4 treatments and their average CPSNP showed significant reduction from 6·86 to 1.29 (P < .001), with a mean 5.57 point decrease (95% CI, 4.90-6.24). Average SMA showed significant reduction from an average of 6.77-1.75 (P < .001), with a mean 5.02-point decrease (95% CI, 4.09-5.96). Pain reductions occurred despite NP aggravating treatment and ongoing usage by 40% of the cohort. 92% of patients reported acute reductions in SMA in the online questionnaire.
CONCLUSION: The significant pain reductions observed may indicate effectiveness of laser acupuncture in reducing both CPSNP and SMA in breast cancer patients post-BCS.
To determine whether young women who have experienced typical vasovagal syncope (tVVS) have altered autonomic response parameters, based on a battery of autonomic tests and maneuvers. Notably, previous studies including small cohorts and a partial list of tests yielded conflicting results. A total of 91 otherwise healthy women were included and divided according to those who had experienced tVVS (39 patients) or not (52 patients). Heart rate variability was evaluated at rest, under strict conditions, during 5 min of standing and during a deep breathing test. Response to Valsalva maneuver and Ewing maneuver were also quantified and compared. Both groups had similar clinical characteristics at baseline. No significant differences were found between the two groups in any of the autonomic parameters evaluated. Autonomic responses in young women who experienced typical vasovagal syncope at baseline were indistinguishable from those who did not. Thus, using non-tilt test autonomic screening tests does not seem to provide diagnostic benefits, and may not be useful in predicting recurrence in this patient population.
The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release.
Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.